

Dear Colleagues,

We are pleased to inform you that the new local Patient Group Direction (PGD) for emergency contraception (Ulipristal acetate and Levonorgestrel) have now been approved and will replace the existing PGDs effective from June 30th.

The new PGDs were developed based on the national PGD guidelines, with consultation and approval from a number of clinical specialists, including medical and pharmaceutical leads, ensuring it meets the highest standards of care.

The key changes in the new Ulipristal Acetate PGD are as follows:

1. Under section 1, subsection 4, this is a new section and is aligned with national standards on ongoing training and competency.
2. Under the inclusion criteria section, bullet point 2 the criteria has changed to presentation within 0 - 120 hours, in the old version this was 72 – 100 hours, this is aligned with the national PGD
3. Acute porphyria is now part of the exclusion criteria, this is aligned with the national PGD

The key changes in the new Levonorgestrel PGD are as follows:

1. Under the inclusion criteria section, bullet point 2 the criteria has changed to presentation within 96 hours, in the old version this was 72 hours
2. Acute porphyria is now part of the exclusion criteria, this is aligned with the national PGD
3. Under section 3, subsection records, there is now a requirement to record the quantity supplied including batch number and expiry date.

If you require any further information or have any questions regarding these changes, please contact Tania Cork in the first instance at taniacork@cpstaffsstoke.org.uk.

Thank you for your attention to this important update.

Kind regards,

Yours sincerely



Dr Tania Cork
Chief Operating Officer
Community Pharmacy Staffordshire & Stoke-on-Trent
Local Pharmaceutical Committee



Stephen Gunter
Director of Public health
Stoke-on-Trent City Council